- Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesDavid B Henley
Lilly Research Laboratories, Indianapolis, IN, USA
Alzheimers Dement 8:407-16. 2012..An understanding of expected rates of adverse events (AEs), overall discontinuations, and discontinuations due to AEs, serious AEs, and deaths would be useful in planning such trials...
- Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's diseaseDavid B Henley
Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
Expert Opin Pharmacother 10:1657-64. 2009..Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit...